Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials

Anita J. Campbell, Steven Y.C. Tong, Joshua S. Davis, Alasdair P.S. Munro, Christopher C. Blyth, Asha C. Bowen

    Research output: Contribution to journalArticle

    Abstract

    Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited.

    Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged.

    Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

    Original languageEnglish
    Article number249
    Pages (from-to)1-4
    Number of pages4
    JournalFrontiers in Pediatrics
    Volume7
    Issue numberJune
    DOIs
    Publication statusPublished - 18 Jun 2019

    Fingerprint

    Bacteremia
    Communicable Diseases
    Staphylococcus aureus
    Clinical Trials
    Pediatrics
    Practice Management
    Anti-Bacterial Agents
    Methicillin-Resistant Staphylococcus aureus
    New Zealand
    Practice Guidelines
    boldenone undecylenate
    Guidelines
    Therapeutics
    Infection
    Research

    Cite this

    @article{698b3b140fb847be8692f9ea92c1481f,
    title = "Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials",
    abstract = "Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.",
    keywords = "Infectious diseases physician, Management, Pediatric, Staphylococcus aureus bacteraemia, Survey",
    author = "Campbell, {Anita J.} and Tong, {Steven Y.C.} and Davis, {Joshua S.} and Munro, {Alasdair P.S.} and Blyth, {Christopher C.} and Bowen, {Asha C.}",
    year = "2019",
    month = "6",
    day = "18",
    doi = "10.3389/fped.2019.00249",
    language = "English",
    volume = "7",
    pages = "1--4",
    journal = "Frontiers in Pediatrics",
    issn = "2296-2360",
    publisher = "Frontiers Research Foundation",
    number = "June",

    }

    Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials. / Campbell, Anita J.; Tong, Steven Y.C.; Davis, Joshua S.; Munro, Alasdair P.S.; Blyth, Christopher C.; Bowen, Asha C.

    In: Frontiers in Pediatrics, Vol. 7, No. June, 249, 18.06.2019, p. 1-4.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials

    AU - Campbell, Anita J.

    AU - Tong, Steven Y.C.

    AU - Davis, Joshua S.

    AU - Munro, Alasdair P.S.

    AU - Blyth, Christopher C.

    AU - Bowen, Asha C.

    PY - 2019/6/18

    Y1 - 2019/6/18

    N2 - Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

    AB - Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

    KW - Infectious diseases physician

    KW - Management

    KW - Pediatric

    KW - Staphylococcus aureus bacteraemia

    KW - Survey

    UR - http://www.scopus.com/inward/record.url?scp=85068842017&partnerID=8YFLogxK

    U2 - 10.3389/fped.2019.00249

    DO - 10.3389/fped.2019.00249

    M3 - Article

    C2 - 31316951

    AN - SCOPUS:85068842017

    VL - 7

    SP - 1

    EP - 4

    JO - Frontiers in Pediatrics

    JF - Frontiers in Pediatrics

    SN - 2296-2360

    IS - June

    M1 - 249

    ER -